22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › MOONLAKE IMMUNOTHERAPEUTICS › 2024-2025

MOONLAKE IMMUNOTHERAPEUTICS 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and MOONLAKE IMMUNOTHERAPEUTICS’s Form 8-K, filed June 6, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 135Asset managers, any item
  • 707Fund votes
  • June 5, 2025Meeting date

Results at a glance

Meeting of June 5, 2025: 5 items on MOONLAKE IMMUNOTHERAPEUTICS’s Form 8-K, filed June 6, 2025: 3 elected · 2 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore MOONLAKE IMMUNOTHERAPEUTICS in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by MOONLAKE IMMUNOTHERAPEUTICS

These tallies are MOONLAKE IMMUNOTHERAPEUTICS’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

MOONLAKE IMMUNOTHERAPEUTICS — official shareholder meeting results, meeting held June 5, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Dr. Jorge Santos da Silva 53,083,965---- 499,1305,738,408 99.1%Elected—
Elect Director: Simon Sturge 52,034,156---- 1,548,9395,738,408 97%Elected—
Elect Director: Dr. Andrew Phillips 53,338,613---- 244,4825,738,408 99.5%Elected—
2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor 59,310,2092,8568,438 --0 99.9%Passed (calculated)—
3. Advisory Vote on Executive Compensation 53,464,199109,9138,983 --5,738,408 99.8%Passed (calculated)—

Source: MOONLAKE IMMUNOTHERAPEUTICS, Form 8-K, filed with the SEC on June 6, 2025 — read the filing on EDGAR.

How asset managers voted at the MOONLAKE IMMUNOTHERAPEUTICS 2024-2025 meeting

135 asset managers disclosed a vote on at least one MOONLAKE IMMUNOTHERAPEUTICS item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Dr. Andrew Phillips

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 53,338,613WITHHELD: 244,482
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Andrew Phillips

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Elect Director: Dr. Andrew Phillips”): 53,338,613 for, 244,482 withheld, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 11,329,105 for, 7,044 withheld, 118,397 abstained.

FOR
FOR: 11,329,105ABSTAIN: 118,397WITHHOLD: 7,044
Largest asset managers voting on “Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholde” at MOONLAKE IMMUNOTHERAPEUTICS, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity4,329,5970 00For
T. Rowe Price2,278,9930 00For
Federated Hermes1,224,3220 00For
HARBOR FUNDS704,8190 00For
ALGER FUNDS533,7560 00For
AllianceBernstein339,0130 00For
AB DISCOVERY GROWTH FUND, INC.201,0280 00For
Putnam191,5000 00For
Columbia Threadneedle187,7200 00For
Victory Capital174,4860 00For
Voya166,9290 00For
BlackRock14,5630 118,3970Mixed
Harbor Funds II102,0200 00For
TIAA97,1750 00For
Manager Directed Portfolios95,7040 00For
Vanguard90,0250 00For
Delaware/Macquarie80,0000 00For
Equitable75,1060 00For
Bridge Builder Trust72,5350 00For
Goldman Sachs71,6230 00For
Principal65,8890 00For
Morgan Stanley41,5020 00For
ALGER PORTFOLIOS30,6050 00For
John Hancock26,8460 00For
ALPS ETF Trust25,4010 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Elect Director: Dr. Jorge Santos da Silva

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 53,083,965WITHHELD: 499,130
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Jorge Santos da Silva

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Elect Director: Dr. Jorge Santos da Silva”): 53,083,965 for, 499,130 withheld, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 11,447,502 for, 7,044 withheld, 0 abstained.

FOR
FOR: 11,447,502ABSTAIN: 0WITHHOLD: 7,044
Largest asset managers voting on “Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholde” at MOONLAKE IMMUNOTHERAPEUTICS, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity4,329,5970 00For
T. Rowe Price2,278,9930 00For
Federated Hermes1,224,3220 00For
HARBOR FUNDS704,8190 00For
ALGER FUNDS533,7560 00For
AllianceBernstein339,0130 00For
AB DISCOVERY GROWTH FUND, INC.201,0280 00For
Putnam191,5000 00For
Columbia Threadneedle187,7200 00For
Victory Capital174,4860 00For
Voya166,9290 00For
BlackRock132,9600 00For
Harbor Funds II102,0200 00For
TIAA97,1750 00For
Manager Directed Portfolios95,7040 00For
Vanguard90,0250 00For
Delaware/Macquarie80,0000 00For
Equitable75,1060 00For
Bridge Builder Trust72,5350 00For
Goldman Sachs71,6230 00For
Principal65,8890 00For
Morgan Stanley41,5020 00For
ALGER PORTFOLIOS30,6050 00For
John Hancock26,8460 00For
ALPS ETF Trust25,4010 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Elect Director: Simon Sturge

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 52,034,156WITHHELD: 1,548,939
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Simon Sturge

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Elect Director: Simon Sturge”): 52,034,156 for, 1,548,939 withheld, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 10,382,221 for, 953,928 withheld, 118,397 abstained.

FOR
FOR: 10,382,221ABSTAIN: 118,397WITHHOLD: 953,928
Largest asset managers voting on “Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholde” at MOONLAKE IMMUNOTHERAPEUTICS, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity4,329,5970 00For
T. Rowe Price2,278,9930 00For
Federated Hermes1,224,3220 00For
HARBOR FUNDS704,8190 00For
ALGER FUNDS533,7560 00For
AllianceBernstein00 0339,013Withhold
AB DISCOVERY GROWTH FUND, INC.00 0201,028Withhold
Putnam191,5000 00For
Columbia Threadneedle00 0187,720Withhold
Victory Capital174,4860 00For
Voya166,9290 00For
BlackRock14,5630 118,3970Mixed
Harbor Funds II102,0200 00For
TIAA97,1750 00For
Manager Directed Portfolios95,7040 00For
Vanguard90,0250 00For
Delaware/Macquarie00 080,000Withhold
Equitable1,8720 073,234Withhold
Bridge Builder Trust72,5350 00For
Goldman Sachs71,6230 00For
Principal00 065,889Withhold
Morgan Stanley41,5020 00For
ALGER PORTFOLIOS30,6050 00For
John Hancock26,8460 00For
ALPS ETF Trust25,4010 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 53,464,199AGAINST: 109,913

Prior year: 100.0% for (June 5, 2024 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 135 asset managers

Description as filed by funds: Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 53,464,199 for, 109,913 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 42 asset managers voting on “Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at MOONLAKE IMMUNOTHERAPEUTICS, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity4,329,5970 00For
T. Rowe Price2,278,9930 00For
Federated Hermes1,224,3220 00For
HARBOR FUNDS704,8190 00For
ALGER FUNDS533,7560 00For
AllianceBernstein339,0130 00For
AB DISCOVERY GROWTH FUND, INC.201,0280 00For
Putnam191,5000 00For
Columbia Threadneedle187,7200 00For
Victory Capital174,4860 00For
Voya166,9290 00For
BlackRock132,9600 00For
Harbor Funds II102,0200 00For
TIAA97,1750 00For
Manager Directed Portfolios95,7040 00For
Vanguard90,0250 00For
Delaware/Macquarie80,0000 00For
Equitable75,1060 00For
Bridge Builder Trust72,5350 00For
Goldman Sachs71,6230 00For
Principal65,8890 00For
Morgan Stanley41,5020 00For
ALGER PORTFOLIOS30,6050 00For
John Hancock26,8460 00For
ALPS ETF Trust25,4010 00For

Fund voting reports, all 42 managers: 11,447,502 for, 0 against, 7,044 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 105 asset managers voting on “Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at MOONLAKE IMMUNOTHERAPEUTICS, 2024-2025
Asset managerForAgainst AbstainWithheldVote
BVF INC/IL19,751,2840 00For
Cormorant Asset Management, LP7,514,3920 00For
Fidelity5,855,9900 00For
T. Rowe Price2,818,4300 00For
Citadel1,409,0550 00For
WESTFIELD CAPITAL MANAGEMENT CO LP1,280,5970 00For
Federated Hermes1,236,6410 00For
Avoro Capital Advisors LLC1,172,0600 00For
AllianceBernstein891,2180 00For
FRED ALGER MANAGEMENT, LLC635,3000 00For
Logos Global Management LP550,0000 00For
MARSHALL WACE, LLP530,9640 00For
Camber Capital Management LP441,0000 00For
Hood River Capital Management LLC368,4380 00For
PICTET ASSET MANAGEMENT SA291,3270 00For
5AM Venture Management, LLC282,3130 00For
Voya227,0530 00For
Victory Capital224,1420 00For
Octagon Capital Advisors LP223,0000 00For
MPM BioImpact LLC222,7330 00For
Putnam191,5000 00For
Vestal Point Capital, LP175,3220 00For
Catalio Capital Management, LP152,0280 00For
Holocene Advisors, LP149,3680 00For
Point72129,1820 00For

Institutional-manager reports, all 105 managers: 48,024,632 for, 104,056 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor

Calculated outcomeAUDIT-RELATEDPassed (calculated)

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 59,310,209AGAINST: 2,856

Prior year: 100.0% for (June 5, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: RATIFICATION, BY ORDINARY RESOLUTION, OF THE SELECTION OF BAKER TILLY US, LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor”): 59,310,209 for, 2,856 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 11,447,502 for, 7,044 abstained.

FOR
FOR: 11,447,502ABSTAIN: 7,044
Largest asset managers voting on “RATIFICATION, BY ORDINARY RESOLUTION, OF THE SELECTION OF BAKER TILLY US, LLP AS THE COMPANY'S INDEPENDENT REG” at MOONLAKE IMMUNOTHERAPEUTICS, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity4,329,5970 00For
T. Rowe Price2,278,9930 00For
Federated Hermes1,224,3220 00For
HARBOR FUNDS704,8190 00For
ALGER FUNDS533,7560 00For
AllianceBernstein339,0130 00For
AB DISCOVERY GROWTH FUND, INC.201,0280 00For
Putnam191,5000 00For
Columbia Threadneedle187,7200 00For
Victory Capital174,4860 00For
Voya166,9290 00For
BlackRock132,9600 00For
Harbor Funds II102,0200 00For
TIAA97,1750 00For
Manager Directed Portfolios95,7040 00For
Vanguard90,0250 00For
Delaware/Macquarie80,0000 00For
Equitable75,1060 00For
Bridge Builder Trust72,5350 00For
Goldman Sachs71,6230 00For
Principal65,8890 00For
Morgan Stanley41,5020 00For
ALGER PORTFOLIOS30,6050 00For
John Hancock26,8460 00For
ALPS ETF Trust25,4010 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Largest MOONLAKE IMMUNOTHERAPEUTICS shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 73,615,396 shares outstanding at the time of that meeting.

Fund voting reports: top MOONLAKE IMMUNOTHERAPEUTICS shareholders by shares voted on “Approval of, on a non-binding, advisory basis, the compensation of the Company's named…”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 5.88%
2T. Rowe Price 3.10%
3Federated Hermes 1.66%
4HARBOR FUNDS 0.96%
5ALGER FUNDS 0.73%
6AllianceBernstein 0.46%
7AB DISCOVERY GROWTH FUND, INC. 0.27%
8Putnam 0.26%
9Columbia Threadneedle 0.26%
10Victory Capital 0.24%
Institutional-manager reports: top MOONLAKE IMMUNOTHERAPEUTICS shareholders by shares voted on “Approval of, on a non-binding, advisory basis, the compensation of the Company's named…”, 2024-2025
#Asset manager % of shares outstanding
1BVF INC/IL 26.83%
2Cormorant Asset Management, LP 10.21%
3Fidelity 7.95%
4T. Rowe Price 3.83%
5Citadel 1.91%
6WESTFIELD CAPITAL MANAGEMENT CO LP 1.74%
7Federated Hermes 1.68%
8Avoro Capital Advisors LLC 1.59%
9AllianceBernstein 1.21%
10FRED ALGER MANAGEMENT, LLC 0.86%

Reported MOONLAKE IMMUNOTHERAPEUTICS holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

MOONLAKE IMMUNOTHERAPEUTICS holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Certain funds managed by BVF Partners L.P.19,751,284 26.83%Proxy statement (DEF 14A), table as of March 15, 2025
BVF PARTNERS L P/IL16,001,284 21.74%Schedule 13D, filed June 29, 2026
Entities affiliated with Bihua Chen8,494,151 11.54%Proxy statement (DEF 14A), table as of March 15, 2025
FMR (Fidelity)6,327,014 8.59%Form 13F, quarter ended March 31, 2025
Deep Track Capital, LP4,610,071 6.26%Schedule 13G, filed November 12, 2025
Dr. Kristian Reich3,079,503 4.18%Proxy statement (DEF 14A), table as of March 15, 2025
Dr. Jorge Santos da Silva3,078,577 4.18%Proxy statement (DEF 14A), table as of March 15, 2025
T. Rowe Price2,973,830 4.04%Form 13F, quarter ended March 31, 2025
Chen Bihua1,994,173 2.71%Schedule 13G, filed October 1, 2025
Citadel Advisors1,497,435 2.03%Form 13F, quarter ended March 31, 2025

Percentages above are of 73,615,396 shares outstanding, as reported by MOONLAKE IMMUNOTHERAPEUTICS on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At MOONLAKE IMMUNOTHERAPEUTICS's shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 135 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 707 separate fund positions. On the most widely held item on that ballot — Approval of, on a non-binding, advisory basis, the compensation of the Company's named… — FOR was 99.8% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: MOONLAKE IMMUNOTHERAPEUTICS's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MOONLAKE IMMUNOTHERAPEUTICS’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

MOONLAKE IMMUNOTHERAPEUTICS proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “MOONLAKE IMMUNOTHERAPEUTICS (MLTX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/moonlake-immunotherapeutics/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.